821 related articles for article (PubMed ID: 26099045)
1. Subclonal diversification of primary breast cancer revealed by multiregion sequencing.
Yates LR; Gerstung M; Knappskog S; Desmedt C; Gundem G; Van Loo P; Aas T; Alexandrov LB; Larsimont D; Davies H; Li Y; Ju YS; Ramakrishna M; Haugland HK; Lilleng PK; Nik-Zainal S; McLaren S; Butler A; Martin S; Glodzik D; Menzies A; Raine K; Hinton J; Jones D; Mudie LJ; Jiang B; Vincent D; Greene-Colozzi A; Adnet PY; Fatima A; Maetens M; Ignatiadis M; Stratton MR; Sotiriou C; Richardson AL; Lønning PE; Wedge DC; Campbell PJ
Nat Med; 2015 Jul; 21(7):751-9. PubMed ID: 26099045
[TBL] [Abstract][Full Text] [Related]
2. The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".
Savas P; Teo ZL; Lefevre C; Flensburg C; Caramia F; Alsop K; Mansour M; Francis PA; Thorne HA; Silva MJ; Kanu N; Dietzen M; Rowan A; Kschischo M; Fox S; Bowtell DD; Dawson SJ; Speed TP; Swanton C; Loi S
PLoS Med; 2016 Dec; 13(12):e1002204. PubMed ID: 28027312
[TBL] [Abstract][Full Text] [Related]
3. Comparative genomic analysis of primary tumors and metastases in breast cancer.
Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
[TBL] [Abstract][Full Text] [Related]
4. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral heterogeneity and subclonal diversification of early breast cancer.
Yates LR
Breast; 2017 Aug; 34 Suppl 1():S36-S42. PubMed ID: 28666921
[TBL] [Abstract][Full Text] [Related]
6. Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
Akahane T; Kanomata N; Harada O; Yamashita T; Kurebayashi J; Tanimoto A; Moriya T
BMC Cancer; 2020 Oct; 20(1):944. PubMed ID: 33004031
[TBL] [Abstract][Full Text] [Related]
7. Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination.
Lawrence-Paul MR; Pan TC; Pant DK; Shih NNC; Chen Y; Belka GK; Feldman M; DeMichele A; Chodosh LA
Genome Med; 2024 Feb; 16(1):26. PubMed ID: 38321573
[TBL] [Abstract][Full Text] [Related]
8. Catalog of genetic progression of human cancers: breast cancer.
Desmedt C; Yates L; Kulka J
Cancer Metastasis Rev; 2016 Mar; 35(1):49-62. PubMed ID: 26951551
[TBL] [Abstract][Full Text] [Related]
9. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
10. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
[TBL] [Abstract][Full Text] [Related]
11. Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing.
Baslan T; Kendall J; Volyanskyy K; McNamara K; Cox H; D'Italia S; Ambrosio F; Riggs M; Rodgers L; Leotta A; Song J; Mao Y; Wu J; Shah R; Gularte-Mérida R; Chadalavada K; Nanjangud G; Varadan V; Gordon A; Curtis C; Krasnitz A; Dimitrova N; Harris L; Wigler M; Hicks J
Elife; 2020 May; 9():. PubMed ID: 32401198
[TBL] [Abstract][Full Text] [Related]
12. Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.
Hagio K; Amano T; Hayashi H; Takeshita T; Oshino T; Kikuchi J; Ohhara Y; Yabe I; Kinoshita I; Nishihara H; Yamashita H
Sci Rep; 2021 Apr; 11(1):8109. PubMed ID: 33854152
[TBL] [Abstract][Full Text] [Related]
13. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
[TBL] [Abstract][Full Text] [Related]
14. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
[No Abstract] [Full Text] [Related]
15. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
16. Molecular Profiling of the Metaplastic Spindle Cell Carcinoma of the Breast Reveals Potentially Targetable Biomarkers.
Vranic S; Stafford P; Palazzo J; Skenderi F; Swensen J; Xiu J; Spetzler D; Gatalica Z
Clin Breast Cancer; 2020 Aug; 20(4):326-331.e1. PubMed ID: 32197944
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
18. Breast tumours maintain a reservoir of subclonal diversity during expansion.
Minussi DC; Nicholson MD; Ye H; Davis A; Wang K; Baker T; Tarabichi M; Sei E; Du H; Rabbani M; Peng C; Hu M; Bai S; Lin YW; Schalck A; Multani A; Ma J; McDonald TO; Casasent A; Barrera A; Chen H; Lim B; Arun B; Meric-Bernstam F; Van Loo P; Michor F; Navin NE
Nature; 2021 Apr; 592(7853):302-308. PubMed ID: 33762732
[TBL] [Abstract][Full Text] [Related]
19. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
[TBL] [Abstract][Full Text] [Related]
20. Combating subclonal evolution of resistant cancer phenotypes.
Brady SW; McQuerry JA; Qiao Y; Piccolo SR; Shrestha G; Jenkins DF; Layer RM; Pedersen BS; Miller RH; Esch A; Selitsky SR; Parker JS; Anderson LA; Dalley BK; Factor RE; Reddy CB; Boltax JP; Li DY; Moos PJ; Gray JW; Heiser LM; Buys SS; Cohen AL; Johnson WE; Quinlan AR; Marth G; Werner TL; Bild AH
Nat Commun; 2017 Nov; 8(1):1231. PubMed ID: 29093439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
